UBU5:F:F-UBS (Irl) ETF Public Limited Company - MSCI USA Value UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 92.41

Change

-1.82 (-1.93)%

Market Cap

USD 0.56B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.53 (-1.10%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.47 (-0.90%)

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.20 (-1.42%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

+0.12 (+1.62%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

-3.24 (-3.57%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 45.80B
0ZC:F Zscaler Inc

-0.40 (-0.22%)

USD 37.92B
BSND:F Danone SA

-0.20 (-1.40%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing UBU5:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.60% 31% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.60% 31% F 48% F
Trailing 12 Months  
Capital Gain -5.10% 41% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.10% 38% F 50% F
Trailing 5 Years  
Capital Gain 55.23% 62% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.23% 62% D 45% F
Average Annual (5 Year Horizon)  
Capital Gain 12.77% 78% C+ 70% C-
Dividend Return 12.77% 75% C 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.84% 52% F 85% B
Risk Adjusted Return 99.46% 89% A- 93% A
Market Capitalization 0.56B 62% D 49% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike